Vis enkel innførsel

dc.contributor.authorØyen, Ninaen_US
dc.contributor.authorOlsen, Sjurdur Frodien_US
dc.contributor.authorBasit, Saimaen_US
dc.contributor.authorLeirgul, Elisabethen_US
dc.contributor.authorStrøm, Marinen_US
dc.contributor.authorCarstensen, Lisbethen_US
dc.contributor.authorGranström, Charlottaen_US
dc.contributor.authorTell, Grethe S.en_US
dc.contributor.authorMagnus, Peren_US
dc.contributor.authorVollset, Stein Emilen_US
dc.contributor.authorWohlfart, Janen_US
dc.contributor.authorMelbye, Madsen_US
dc.PublishedØyen N, Olsen SF, Basit S, Leirgul E, Strøm M, Carstensen L, Granström C, Tell GST, Magnus P, Vollset SE, Wohlfart J, Melbye M. Association Between Maternal Folic Acid Supplementation and Congenital Heart Defects in Offspring in Birth Cohorts From Denmark and Norway. Journal of the American Heart Association. 2019;8(6):e011615eng
dc.description.abstractBackground: Evidence linking individual‐level maternal folic acid supplementation to offspring risk of congenital heart defects is lacking. We investigated whether folic acid supplementation in early pregnancy reduces offspring risk of heart defects in 2 large birth cohort studies. Methods and Results: Women recruited in early pregnancy within the DNBC (Danish National Birth Cohort), 1996–2003, and MoBa (Norwegian Mother and Child Cohort Study), 2000–2009, were followed until delivery. Information on periconceptional intake of folic acid and other supplements was linked with information on heart defects from national registers. Among 197 123 births, we identified 2247 individuals with heart defects (114/10 000). Periconceptional (4 weeks before through 8 weeks after conception) use of folic acid plus other supplements (54.8%), folic acid only (12.2%), and non–folic acid supplements (5.0%) were compared with no supplement use (28.0%); the adjusted relative risks of heart defects were 0.99 (95% CI, 0.80–1.22), 1.08 (95% CI, 0.93–1.25), and 1.07 (95% CI, 0.97–1.19), respectively. For initiation of folic acid in the preconception period weeks −4 to −1 (33.7%) and the postconception periods 0 to 4 weeks (15.5%), 5 to 8 weeks (17.8%), and 9 to 12 weeks (4.6%), compared with no or late folic acid intake (29.1%), relative risks of heart defect were 1.11 (95% CI, 1.00–1.25), 1.09 (95% CI, 0.95–1.25), 0.98 (95% CI, 0.86–1.12), and 0.97 (95% CI, 0.78–1.20), respectively. Relative risks of severe defects, conotruncal defects, and septal defects showed similar results. Conclusions: Folic acid was not associated with offspring risk of heart defects, including severe defects, conotruncal defects, or septal defects.en_US
dc.publisherWiley Open Accesseng
dc.rightsAttribution CC BYeng
dc.subjectcongenital cardiac defecteng
dc.subjectMoBa (Norwegian Mother and Child Cohort Study)eng
dc.subjectprospective cohort studyeng
dc.titleAssociation Between Maternal Folic Acid Supplementation and Congenital Heart Defects in Offspring in Birth Cohorts From Denmark and Norwayen_US
dc.typePeer reviewed
dc.typeJournal article
dc.rights.holderCopyright 2019 The Authors
dc.source.journalJournal of the American Heart Association

Tilhørende fil(er)


Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution CC BY
Med mindre annet er angitt, så er denne innførselen lisensiert som Attribution CC BY